This meeting took place in 2019



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Vaccines (L2)


Organizer(s) LĂ©lia Delamarre, Robert A. Seder and Nina Bhardwaj
January 20—24, 2019
Fairmont Hotel Vancouver • Vancouver, British Columbia Canada
Discounted Abstract Deadline: Oct 16, 2018
Abstract Deadline: Oct 24, 2018
Scholarship Deadline: Oct 16, 2018
Discounted Registration Deadline: Nov 27, 2018

Organized in collaboration with Cancer Research UK

Sponsored by BioLegend, Inc., Genentech, Inc. and Pfizer Inc.

Summary of Meeting:
The success of immunotherapy in the treatment of cancer patients has proved the long-standing hypothesis that endogenous adaptive immune responses against the tumor can be harnessed to mediate protection by immune checkpoint blockade. This approach has shown impressive control of disease and improved survival in up to 50% of patients with certain tumors. Genetic and immune analysis of human cancers suggests that one mechanism of resistance to immune checkpoint blockade may be due to lack of tumor-specific T cells. In principle, vaccines have the potential to overcome this defect by either expanding low-level existing tumor-specific T cell responses or priming tumor-specific T cells. Recent advances in next-generation sequencing have improved our understanding of defining cancer antigens. Application of this will require vaccine delivery approaches that can induce potent and broad T cell immunity in an efficient manner for personalized therapy. This Keystone Symposia conference will highlight recent insights in the characterization of immunogenic cancer antigens, the biology and underlying mechanisms of T cell priming, and the development of novel approaches designed to expand T cell responses. Part of the meeting will also be devoted to the development of technologies to monitor T cell responses in response to immune interventions.

View Meeting Program

Scholarships/Awards

Cancer Research UK Scholarship Recipients

Elham Beyranvand Nejad
Leiden University Medical Center, Netherlands

National Cancer Institute (NCI)/National Center for Advancing Translational Sciences (NCATS) Scholarship Recipients

Mark Aleynick
Icahn School of Medicine at Mount Sinai, USA

Selma Bekri
Icahn School of Medicine at Mount Sinai, USA

Binbin Chen
Stanford Medical School, USA

Cansu Cimen Bozkus
Icahn School of Medicine at Mount Sinai, USA

Alessia Melacarne
Humanitas University, Italy

Zhen Zeng
University of Queensland, Australia